Sasineprocel’s encouraging Phase I/IIa data positions autologous iPSC-derived dopaminergic neuron therapy as a potential monotherapy challenger in Parkinson’s disease (PD), signalling a shift toward regenerative treatment strategies beyond symptomatic dopamine replacement. Strong safety, graft survival and functional improvements underscore its disruptive promise, though cost, reimbursement hurdles and upcoming Phase III validation will determine its real-world clinical and commercial viability going forward, says GlobalData, a leading intelligence and productivity platform.
On 18 March, at the AD/PD 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, Aspen Neuroscience announced 12-month data from the ongoing Phase I/IIa ASPIRO trial (NCT06344026) of its autologous induced pluripotent stem cell (iPSC) derived dopaminergic neuron precursor cell (DANPC) therapy, sasineprocel.
In the first eight treated patients, investigators reported numerical improvements across motor function, activities of daily living, patient-reported outcomes and quality of life, while also showing imaging evidence of graft survival and engraftment. This indicates that sasineprocel could one day reach the market as a first-in-class iPSC-derived cell therapy for PD.
Jos Opdenakker, Neurology Analyst at GlobalData, comments: “No serious surgical adverse events (AEs) associated with the bilateral intracerebral administration were reported, and neither were graft-induced dyskinesia nor symptomatic hemorrhage or infarction. Clinically, sasineprocel elicited improvements in mean good ON time, the Movement Disorder Society – Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part II and Part III OFF scores, and quality of life improvements as assessed by The Parkinson’s Disease Questionnaire (PDQ-39) as well.”
Investigators also reported that FDOPA PET imaging, a specialized molecular imaging procedure used to produce high-resolution 3D images of brain dopaminergic activity, showed cell survival and successful engraftment, adding biological support to the observed clinical changes.
Opdenakker adds: “This clinical data indicates that sasineprocel may have a future as a monotherapy competing with dopaminergic or anti-PD therapies. However, as a monotherapy, sasineprocel will face competition from well-established therapies such as levodopa, dopamine agonists (DA), and monoamine oxidase B inhibitors (MAO-B).”
According to GlobalData’s Drugs Database, six dopamine agonists are currently marketed across the seven major pharmaceutical markets (the US, France, Germany, Italy, Spain, the UK, and Japan), many of which are available as generics.
Sasineprocel could also face competition from other cell therapies being developed for PD such as Bluerock Therapeutics’ bemdaneprocel, which is in Phase III development.
Opdenakker continues: “As an iPSC-derived cell-therapy, sasineprocel is likely to be far more expensive than traditional PD therapies, meaning it could face challenges in receiving regulatory approval, being reimbursed, and ultimately gaining traction in the market. However, as an iPSC-derived cell-therapy, it has a novel, potentially first-in-class, non-dopaminergic mechanism, which differentiates it from competitors.”
The question for clinicians will be how to integrate such a unique treatment in routine PD care. Aspen will need to demonstrate that sasineprocel can show superior efficacy and safety over marketed dopaminergic therapies in large Phase III clinical trials or engage in head-to-head studies for direct comparison. Aspen plans to start a large Phase III trial later in 2026, and this will be critical in discerning whether these results can be replicated in a larger, controlled population.
Opdenakker concludes: “While the ASPIRO trial results highlight sasineprocel’s potential as a novel, first in class iPSC derived therapy, its ultimate success will depend on proving superior efficacy and cost effectiveness in larger Phase III trials, which will determine its viability alongside or in place of established dopaminergic treatments.”
